首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 生物科技 > 再生醫學 > 細胞治療市場
產業/市場分類
生物科技 (1470)
分子標靶治療學 (51)
生技設備 (321)
生物材料 (55)
生物標記 (157)
以基因為基之藥物開發 (201)
再生醫學 (120)
抗體和免疫 (187)
個人化醫學 (54)
基因治療學和RNAi (101)
市場調查報告書

細胞治療市場

Cell Therapy Markets

出版商 Trimark Publications
出版日期 2007年07月 商品編碼 53079
內容資訊 英文 270 pages
價格
US $ 3400 PDF by E-mail (Single User License)
US $ 6800 PDF By E-mail (Unlimited User License)


細胞治療市場 是由出版商Trimark Publications在2007年07月所出版的。 這份英文市場調查報告書包含270 pages 價格從美金3400起跳。

目錄

Abstract

Cell therapy technologies and methods have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Cell therapy is bound to become a part of medical practice. Unlike organs, cells are a potentially renewable resource for body repair. The goal of this TriMark Publications report is to review the market for cell therapy products using screening reagents and instruments for analysis of individual components in tissue samples, blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including the research labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of cell therapy and the factors that influence purchases are discussed. The study surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the cell therapy market in the U.S. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company' s market position.

Table of Contents

1. Overview

  • 1.1 Statement of Report
  • 1.2 About this Report
  • 1.3 Scope of the Report
  • 1.4 Objectives
  • 1.5 Methodology
  • 1.6 Executive Summary

2. Overview of the Science of Cell Therapy

  • 2.1 Cell Therapy Technologies
    • 2.1.1 Stem Cell Therapies
    • 2.1.2 Umbilical Cord Blood Stem Cell Transplant
    • 2.1.3. Cord Blood Collection, Transfusion and Storage Market
    • 2.1.4 Cell Therapy and Related Technologies
  • 2.2 Organ Transplantation to Cell Therapy
  • 2.3 Sources of Cells for Therapy
  • 2.4 Types of Cells Available for Therapy
    • 2.4.1 Cells and Protein/Gene Therapy
    • 2.4.2 Cell Therapy and Regenerative Medicine
    • 2.4.3 Cells Therapy and Tissue Engineering
  • 2.5 Cell Therapy Compared to Small Molecule Drugs, Biologics and Tissue Engineered Products
  • 2.6 What Conditions are Amenable to Cell Therapy and Why?
    • 2.6.1 Wounds and Burns
    • 2.6.2 Aesthetic Medicine: Botox and Collagen
    • 2.6.3 Cell Therapy for Bones and Joints
    • 2.6.4 Blood Component Therapy
    • 2.6.5 Immunotherapy for Cancer
    • 2.6.6 Cardiovascular Disorders
    • 2.6.7 Diabetes Mellitus
    • 2.6.8 Neurological Disorders
    • 2.6.9 Urinary Incontinence
    • 2.6.10 Cells for Drug Discovery
  • 2.7 Properties of Stem Cells and Their Classification
  • 2.8 Stem Cell Differentiation
  • 2.9 Stem Cell Therapy
  • 2.10 Market Opportunity in the Stem Cell Marketplace
  • 2.11 Potential Stem Cell Commercial Applications
    • 2.11.1 Cord Blood Stem Cells and Cord Blood Stem Cell Banking: Current Market Environment and Opportunity
    • 2.11.2 Qualitative and Quantitative Trends in the Stem Cells Space
    • 2.11.3 Utilization of the Different Classes of Stem Cells
    • 2.11.4 Quantitative Metrics of the Stem Cell Research Marketplace: Number of Experiments Performed, Research Spending Trends and Growth

3. The Cell Therapy Market

  • 3.1 Market Overview
  • 3.2 The Overall Cell Therapy Market Opportunity
  • 3.3 Stem Cell Therapies
    • 3.3.1 Cell Therapy/Regenerative Therapy Markets
    • 3.3.2 Market Size According to Geographical Areas
  • 3.4 Competitive Landscape of the Stem Cells Marketplace
    • 3.4.1 Evolution of Research Activities with the Different Types of Stem Cells: Current Usage Trends and Usage in 12 to 18 Months
    • 3.4.2 Types of Research Activities the End-User Community Performing with the Different Types of Stem Cells
    • 3.4.3 Challenges Facing Stem Cell Researchers
    • 3.4.4 Market Drivers
    • 3.4.5 Research Questions Being Addressed in the Stem Cells Space
    • 3.4.6 Focus on Cancer Stem Cells
    • 3.4.7 Summary of Challenges and Opportunities in the Stem Cells Space Based on TriMark' s Analysis
    • 3.4.8 Unmet Product Needs in the Stem Cells Research Space and Licensing/IP Constraints
  • 3.5 Competitive Landscape
    • 3.5 1 Cell Therapy Market
    • 3.5.2 Stem Cells Marketplace
  • 3.6 Market Shares of Companies Offering Different Stem Cells
  • 3.7 SWOT Analysis of the Major Stem Cell Market Segments
  • 3.8 Market Size and Forecasts
    • 3.8.1 The Research Market
    • 3.8.2 Cell Therapy/Regenerative Therapy Markets

4. The Technology of Cell Therapy

  • 4.1 Growing Cells-An Overview from Source to Product
  • 4.2 Cell Culture
    • 4.2.1 Cell Culture Process
    • 4.2.2 Cell Culture Applications
    • 4.2.3 Types of Mammalian Cultures
    • 4.2.4 Plant Cell Culture
    • 4.2.5 Commercialization of Cell Culture Products
    • 4.2.6 Companies in Cell Culture Technology
  • 4.3 Cell Lines
  • 4.4 Large Scale Manufacturing
  • 4.5 Making Product, Shipping, Distribution and Storage
  • 4.6 Quality Control and Safety
  • 4.7 Delivery Systems for Cell Therapy
  • 4.8 Basic Technologies for Cell Therapy
    • 4.8.1 Flow Cytometry and Cell Sorting
  • 4.9 Cell Seperation Techniques
    • 4.9.1 Density-Based Isolation Methods
      • 4.9.1.1 Ficoll-hypaque-based Density Gradient System NIM2
      • 4.9.1.2 Lymphocyte Separation Medium
      • 4.9.1.3 Density Gradient Media
    • 4.9.2 Micro Sieves
    • 4.9.3 Antibody-based Cell Separation Techniques
    • 4.9.4 Magnet Sorting
    • 4.9.5 Automated Seperation Procedures
    • 4.9.6 Aldesorter System for Isolation of Stem Cells
  • 4.10 Cell Preservation Technology
  • 4.11 Selective Expansion of T Cells for Immunotherapy
  • 4.12 Devices for Delivery of Cell Therapy
    • 4.12.1 Artificial Cells
    • 4.12.2 Cell Encapsulation
      • 4.12.2.1 Range of Therapeutic Tretaments
      • 4.12.2.2 Technical Barriers
      • 4.12.2.3 Current Challenges
    • 4.12.3 Therapeutic Applications of Encapsulated Cells
      • 4.12.3.1 Cancer Therapy
      • 4.12.3.2 Therapeutic Genes
      • 4.12.3.3 Retinal Disease
    • 4.12.4 Use of Microencapsulated Genetically Modified Cells
    • 4.12.5 Nanoparticle-Aptamer Bioconjugates

5. Stem Cells

  • 5.1 Basic Properties of Stem Cells and Their Classification
    • 5.1.1 Embryonic Stem Cells
    • 5.1.2 Embryonic Germ Cells
  • 5.2 Sources of Stem Cells
  • 5.3 Challenges Facing Stem Cell Researchers
  • 5.4 Stem Cells for Drug Toxicity Screening
  • 5.5 Market Analysis of the Stem Cells Space

6. Clinical Applications of Cell Therapy

  • 6.1 Cell Therapy for Hematological Disorders
    • 6.1.1 Hematopoietic Cells for Hematologic Diseases and to Prevent Immune Rejection
    • 6.1.2 Hematopoietic Cytokines
    • 6.1.3 Prochymal™ for the Treatment of Acute Graft versus Host Disease
    • 6.1.4 Cell/Gene Therapy of Hemophilia B
    • 6.1.5 Ex Vivo Cell/Gene Therapy of Hemophilia A
    • 6.1.6 Therapies for the Hemophilia Market
    • 6.1.7 Stem Cell Transplant for Sickle Cell Anemia
    • 6.1.8 Modified Hematopoietic Stem Cells for Chronic Acquired Anemias
    • 6.1.9 Stem Cell Therapy of Hemoglobinopathies
    • 6.1.10 Future Prospects of Cell Therapy of Hematological Disorders
  • 6.2 Cell Therapy for Immunological Disorders
    • 6.2.1 Treatment of Crohn' s Disease with Stem Cells
  • 6.3 Cell therapy for Diabetes Mellitus
    • 6.3.1 Islet Cells for Diabetes
  • 6.4 Cell Therapy for Liver Disorders
    • 6.4.1 About Liver Disease
    • 6.4.2 Technology Summary
  • 6.5 Cell Therapy for Renal Disorders
    • 6.5.1 Human Renal Epithelial Cells Administered Ex Vivo
  • 6.6 Cell Therapy for Disorders of Bones and Joints
    • 6.6.1 Osteoblasts for Osteoporosis and Non-Union Bone Fractures
    • 6.6.2 Chondrocytes for Osteoarthritis and the Use of hESCs
    • 6.6.3 Knee Injury Treatment for Meniscectomy Patients Using Mesenchymal Stem Cells
  • 6.7 Wound Healing: Skin and Soft Tissue Repair
    • 6.7.1 Autologous Living Cell Therapy
    • 6.7.2 Cell Therapy for Corneal Repair
      • 6.7.2.1 Current Clinical Status for Cornea Disease and Transplant
      • 6.7.2.2 Regenerative Cornea Product from Cellseed
  • 6.8 Role of Cells in Tissue Engineering and Reconstructive Surgery
  • 6.9 Cell Therapy for Cardiovascular Disorders
    • 6.9.1 Introduction to Cardiovascular Disorders
      • 6.9.1.1 Myocardial Infarction (Heart Attack)
      • 6.9.1.2 Congestive Heart Failure (CHF)
      • 6.9.1.3 Heart Failure Classification
      • 6.9.1.4 Diagnosis and Management of Heart Failure
      • 6.9.1.5 Drug Therapies
      • 6.9.1.6 Bi-ventricular Pacers
      • 6.9.1.7 Heart Transplantation and Other Surgical Procedures
      • 6.9.1.8 Ventricular Assist Devices
      • 6.9.1.9 Market Potential
      • 6.9.1.10 Limitations of Current Therapies for Myocardial Ischemic Disease
    • 6.9.2 Sector Overview of Cell Based Cardiac Repair
      • 6.9.2.1 Categories of Cell Types for Cell Therapy
        • 6.9.2.1.1 Autologous Skeletal Myoblasts
        • 6.9.2.1.2 Cardiocytes
        • 6.9.2.1.3 Mesenchymal Stem Cell (MSC)
        • 6.9.2.1.4 Bone Marrow Derived Stem Cells
        • 6.9.2.1.5 Fetal Cardiomyocytes
        • 6.9.2.1.6 Smooth Muscle Cells
        • 6.9.2.1.7 Immortalized Myoblasts
        • 6.9.2.1.8 Syngeneic Skeletal Myoblasts
        • 6.9.2.1.9 Fibroblasts
        • 6.9.2.1.10 Embryonic Stem Cell
        • 6.9.2.1.11 Bone Marrow Derived Stromal Cells
      • 6.9.2.2 Current Cell Therapies for Myocardial Ischemic Disease
        • 6.9.2.2.1 Cardiomyocytes for Heart Disease
        • 6.9.2.2.2 Mesenchymal Stem Cells (MSCs) Provacel™, (Osiris Therapeutics)
        • 6.9.2.2.3 Living Regenerative Cardiac Patch (Cellseed)
        • 6.9.2.2.4 Bioheart' s MyoCell
        • 6.9.2.2.5 Viacell' s Unrestricted Somatic Stem Cells (USSCs)
        • 6.9.2.2.6 Mytogen' s Autologous Myoblasts
    • 6.9.3 Research Methods for Delivery of Cells to the Heart
      • 6.9.3.1 Cell Transplantation for Cardiac Repair
      • 6.9.3.2 Using Nanofibers to Deliver Insulin Growth Factor
    • 6.9.4 Role of Stem Cells in Repair of the Heart
      • 6.9.4.1 Cardiac Autologous Stem Cells
        • 6.9.4.1.1 Expansion of Stem Cells
        • 6.9.4.1.2 Role of ESCs in Repair of the Heart
        • 6.9.4.1.3 Transplantation of BMPCs
        • 6.9.4.1.4 Transplantation of CMPCs
        • 6.9.4.1.5 Transplantation of hESCs
        • 6.9.4.1.6 Transplantation of Skeletal Myoblasts
        • 6.9.4.1.7 Transplantation of Autologous Angiogenic Cell Precursors
        • 6.9.4.1.8 Regeneration of Chronic Myocardial Infarcts by HSC Therapy
        • 6.9.4.1.9 Transplantation of Adipose-Derived Stem Cells
        • 6.9.4.1.10 Intracoronary Infusion of Bone Marrow-Derived Cells for AMI
        • 6.9.4.1.11 Human Mesenchymal Stem Cells for Cardiac Regeneration
        • 6.9.4.1.12 Simultaneous Transplantation of Autologous MSCs and Skeletal Myoblasts
    • 6.9.5 Role of Genetically Modified Cells
      • 6.9.5.1 Gene Therapy Using Modified Stem Cells
      • 6.9.5.2 Use of Cells Secreting Vascular Endothelial Growth Factor
    • 6.9.6 Cell Therapy for Congestive Heart Failure
      • 6.9.6.1 Angiocell Gene Therapy for Congestive Heart Failure
    • 6.9.7 Role of Cell Therapy in Cardiac Arrhythmias
      • 6.9.7.1 Genetically Modified Cell Grafts
      • 6.9.7.2 Cardiomyocyte Cell Grafts
      • 6.9.7.3 Antiarrhythmic Potential of Cell Therapy Strategies
      • 6.9.7.4 Vectors for Gene Therapy
      • 6.9.7.5 Methods of Gene Delivery
      • 6.9.7.6 Gene Therapy in Cardiac Arrhythmias
      • 6.9.7.7 Current Problems with Gene Therapy
    • 6.9.8 Cell Therapy for Cardiac Tissue Engineering of Blood Vessels with Cells
      • 6.9.8.1 Fetal Cardiomyocytes Seeding in Tissue-Engineered Cardiac Grafts
    • 6.9.9 Competitive Landscape for Cell Therapy Based Cardiovascular Products
    • 6.9.10 Evaluation of Cell Therapy as Therapy for Heart Disease
  • 6.10 Cell Therapy for Cancer
    • 6.10.1 Introduction
    • 6.10.2 Cell Therapy Technologies for Cancer
    • 6.10.3 Cellular Immunotherapy for Cancer Treatments for Cancer by ExVivo Mobilization of Immune Cells
    • 6.10.4 Alternative Cancer Treatment Market
    • 6.10.5 Autologous Tumor Cell Vaccines and Dendritic Cell Therapy
    • 6.10.6 The Use of Dendritic Cells for Cancer Vaccination
      • 6.10.6.1 Collection of Cells
      • 6.10.6.2 Basics of Dendritic Cell Vaccines
      • 6.10.6.3 Dendritic Cells Treated with Purified Tumor Antigen
      • 6.10.6.4 Stimulation of Immature Dendritic Cells to Become Mature Dendritic Cells
      • 6.10.6.5 Cell Fragments of Dendritic Cells Primed with Tumor Cell Antigens
    • 6.10.7 Gene Therapy
    • 6.10.8 Stem Cell-Based Anticancer Therapies
    • 6.10.9 Other Cell Therapy Vaccines
    • 6.10.10 Stem Cell Transplantation in Cancer
      • 6.10.10.1 Peripheral Blood Stem Cell Transplantation
      • 6.10.10.2 Autologous Stem Cell Transplantation
      • 6.10.10.3 Complications of Stem Cell Transplants in Cancer
      • 6.10.10.4 Mesenchymal Stem Cell Transplantation in Cancer
      • 6.10.10.5 Umbilical Cord Blood Transplant for Leukemia
      • 6.10.10.6 Hesc-Derived NK Cells for Treatment of Cancer
    • 6.10.11 Innovations in Cell-Based Therapy of Cancer
      • 6.10.11.1 Cancer Therapy Based on NK-92 Cells
      • 6.10.11.2 Myoblast Mediated Gene Therapy
    • 6.10.12 Cancer Stem Cells
    • 6.10.13 Mesenchymal Stem Cells for the Treatment of Gliomas
    • 6.10.14 Companies Involved in Cell-Based Cancer Therapy
    • 6.10.15 Stem Cell-Based Anti-Cancer Therapies
  • 6.11 Cell Therapy for Neurological Disorders
    • 6.11.1 Oligodendrocytes for Spinal Cord Injury and Dopaminergic Neurons for Parkinson' s Disease
    • 6.11.2 Neural Stem Cells as a Treatment for Neuronal Ceroid Lipofuscinosis
    • 6.11.3 Epilepsy and Neuropathic Pain Markets
    • 6.11.4 Delivery of Naturally Occurring Neurotrophic Factors
    • 6.11.5 Repairing the Nervous System
    • 6.11.6 Genes Permanently Incorporated into Targeted Cells
    • 6.11.7 Neurological Disorders Responding to Neurotrophic Factors
    • 6.11.8 Ceregene' s Products
    • 6.11.9 Parkinson' s Disease
      • 6.11.9.1 Introduction
      • 6.11.9.2 Market Opportunity
      • 6.11.9.3 Stem Cell Line for Functional Dopaminergic Neurons
  • 6.12 Cell Therapy for Stroke
    • 6.12.1 Introduction
    • 6.12.2 Market Opportunity
    • 6.12.3 Stem Cell Therapy for Chronic Stroke Disability
  • 6.13 Cell Therapy for Dental Treatments
  • 6.14 Gene Therapy
    • 6.14.1 Vehicles for Gene Transfer
    • 6.14.2 Viral Vectors for Gene Therapy
    • 6.14.3 Nonviral Vectors: Liposomes
    • 6.14.4 Gene Therapy for Hematopoietic Derived Diseases
  • 6.15 hESC-Derived Hepatocytes for Drug Screening and Toxicology

7. Ethics, Regulation and Funding

  • 7.1 Ethics
  • 7.2 The U.S. Position on hESC Research
  • 7.3 Regulation and Legislation
    • 7.3.1 Regulations on Stem Cell Research
    • 7.3.2 Regulation of Tissue Engineered Products
  • 7.4 Investment
  • 7.5 Interdisciplinary and Public-Private Partnerships
  • 7.6 Corporate Partnerships
    • 7.6.1 ReNeuron and CellSeed Collaboration Using ReNcellTM Liver Cell Lines
    • 7.6.2 Plureon Corporation in Agreement with BD
    • 7.6.3 Icoria Inc. Research Agreement with Vesta Therapeutics
  • 7.7 Corporate Mergers
    • 7.7.1 GenVec' s Acquisition of Diacrin, Inc.
    • 7.7.2 Genvec Transferred its Cell Transplantation Assets to Mytogen, Inc.
  • 7.8 European Regulation on Advanced Cell Therapies
  • 7.9 Processing Autologous Cell Products-Discussing the Regulatory and Commercial Impact of Patient-Specific Therapies
  • 7.10 Stem Cell Research Funding

8. Future Directions in Cell Therapy

  • 8.1 Cell Therapy Future Markets According to Therapeutic Area
    • 8.1.1 Brain and Central Nervous System Applications
    • 8.1.2 Cardiology Applications
    • 8.1.3 Diabetes Applications
    • 8.1.4 Tissues and Organs
    • 8.1.5 Other Applications
  • 8.2 Unmet Market Needs in Cell Therapy
  • 8.3 Future Prospects of Cell Therapy
    • 8.3.1 Autologous Stem Cells
    • 8.3.2 Pluripotential Stem Cells Lines
    • 8.3.3 Angiogenesis
    • 8.3.4 Reprogramming Stem Cells
  • 8.4 Clinical Trials in Cell Therapy
  • 8.5 Analytical Tools for Cell Therapy
  • 8.6 Ethical Concerns of Cloning for Reproductive Purposes
    • 8.6.1 Ethical Concerns
    • 8.6.2 Policy and Regulation
  • 8.7 Cloning for the Isolation of Human ES Cells
    • 8.7.1 Ethical Concerns
    • 8.7.2 Policy and Regulation
  • 8.8 Somatic Cell Nuclear Transfer Generating Pluripotential Stem Cells
  • 8.9 Funding of Stem Cell Research from Non-Federal Sources
  • 8.10 Industry Challenges for Cell Therapy Manufacturing
    • 8.10.1 Cost Challenges to Manufacturing Processes
    • 8.10.2 Supply Challenges for Current Manufacturing Processes
  • 8.11 Future Prospects of Cell Therapy
  • 8.12 Challenges for Cell Therapy
  • 8.13 Therapeutic Cloning
  • 8.14 Future Market Potential of Adult Versus Embryonic Stem Cells
  • 8.15 Challenges of Developing a Cell Therapy Product Compared to a Conventional Drug Product
  • 8.16 Transition from a Techology Driven Company to a Product Driven Company
  • 8.17 Exploiting Technology Platforms for Commercial Success
  • 8.18 At What Point Do You Seek a Partner in Cell Therapy Development
  • 8.19 Cell and Tissue Therapies Product Development and Manufacture
    • 8.19.1 What Commercialization Models are Emerging to Cope with Complex Manufacturing Required by Cell Therapies?
    • 8.19.2 Optimizing Product Development, Manufacture and Commercialization of Autologous and Allogeneic Cell Therapies

9. Company Profiles

  • 9.1 Aastrom Biosciences
  • 9.2 Advanced Cell Technology
  • 9.3 Advanced Cell Therapeutics
  • 9.4 Aldagen
  • 9.5 AllCells, LLC.
  • 9.6 AmCyte
  • 9.7 Arthro Kinetics
  • 9.8 AstraZeneca
  • 9.9 Australian Stem Cell Centre
  • 9.10 Axordia
  • 9.11 BioE
  • 9.12 Bioheart
  • 9.13 BioTransplant Incorporated
  • 9.14 BrainStorm Cell Therapeutics
  • 9.15 Cambrex
  • 9.16 Cardio3
  • 9.17 Cartela
  • 9.18 Cellartis
  • 9.19 Cellerant Therapeutics
  • 9.20 CellSeed Inc.
  • 9.21 Cellular Dynamics International
  • 9.22 Ceregene, Inc.
  • 9.23 Cryo-Cell International
  • 9.24 Cytori Therapeutics
  • 9.25 ES Cell International
  • 9.26 Fraunhofer Institute for Cell Therapy and Immunology
  • 9.27 Gamida Cell Therapeutics
  • 9.28 GE Healthcare
  • 9.29 GenVec, Inc.
  • 9.30 Geron
  • 9.31 GlaxoSmithKline
  • 9.32 Intercytex
  • 9.33 Invitrogen
  • 9.34 Institute for Stem Cell Research, University of Edinburgh
  • 9.35 Isolagen
  • 9.36 Lexicon Genetics
  • 9.37 Lund Stem Cell Center, Lund University
  • 9.38 MaxCyte
  • 9.39 Miltenyi Biotec
  • 9.40 NeuroNova
  • 9.41 Norwegian Center for Stem Cell Research
  • 9.42 NovaThera
  • 9.43 NsGene
  • 9.44 Osiris Therapeutics
  • 9.45 Pfizer
  • 9.46 Plureon
  • 9.47 Pluristem Life Systems
  • 9.48 Progenitor Cell Therapy, LLC
  • 9.49 Regenerative Medicine Network (RegMedNet), University of Leipzig
  • 9.50 RenaMed Biologics
  • 9.51 ReNeuron
  • 9.52 StemCells, Inc.
  • 9.53 Stem Cell Innovations
  • 9.54 Stem Cell Sciences
  • 9.55 StemCell Technologies
  • 9.56 Thermogenesis
  • 9.57 TiGenix
  • 9.58 Tissue Engineering and Regenerative Medicine Centre, Imperial College London
  • 9.59 UK Stem Cell Bank
  • 9.60 UK Stem Cell Foundation
  • 9.61 ViaCell
  • 9.62 Vesta Therapeutics, Inc.
  • 9.63 VistaGen Therapeutics
  • 9.64 Wolfson Centre for Age-Related Diseases, King' s College, London
  • 9.65 AlphaCord
  • 9.66 Celgene
  • 9.67 Cord Blood Registry
  • 9.68 Angiogene
  • 9.69 EntreMed

Appendix

  • Sources of Umbilical Cord Blood for Stem Cell Research
  • National Marrow Donor Program
  • For Profit Storage of Cord Blood
  • Stem Cells from Frozen Embryos
  • Stem Cell Policy Statement
  • Glossary of Terms in Cell Biology

LIST OF TABLES

  • Table 2.1: U.S. Companies Involved in Cord Blood Banking
  • Table 2.2: U.K. Companies Involved in Cord Blood Banking
  • Table 2.3: Waiting List for Organ Transplants in U.S.
  • Table 2.4: Number of Organ Transplants Carried out in U.S., January-March 2006
  • Table 2.5: Sources of Cells for Therapy and Other Applications
  • Table 2.6: U.S. Wound Care Market, 2003-2012
  • Table 2.7: Stem Cell Therapeutics for Orthopedic Disease in Development
  • Table 2.8: Cellular Therapies in Orthopedics Trauma and Fracture Markets
  • Table 2.9: Stem Cell-based Therapeutics for Cardiac and Ischemic Diseases in Development
  • Table 2.10: Stem Cell-Based Therapeutics for Vascular Diseases in Development
  • Table 2.11: Stem Cell Therapeutics for Type I Diabetes in Development
  • Table 2.12: Stem Cell Therapeutics for Neurological Disease in Development
  • Table 2.13: Key Properties of Stem Cells
  • Table 2.14: Sources of Human Stem Cells
  • Table 2.15: The Different Types of Stem Cells and their Properties
  • Table 2.16: Adult Stem Cell (ASC) Differentiation Properties
  • Table 2.17: Characteristics of Different Stem Cell Types and Associated Market Opportunities
  • Table 2.18: Segmentation of the Stem Cell Market by Type/Lineage of Stem Cell
  • Table 2.19: Selected Cord Blood Banks in the U.S.
  • Table 2.20: Selected Companies in the Cord Blood Stem Cell Technology and Therapeutics Development Space
  • Table 3.1: Worldwide Cell Therapy Markets, 2005-2012
  • Table 3.2: Worldwide Stem Cell, Cytokine, and Growth Factor Cell Therapy Markets, 2005-2012
  • Table 3.3: The World Market for Stem Cell Products and Services, 2005-2012
  • Table 3.4: Breakout of the Stem Cell Research Market: Current Research Efforts with Different Types of Stem Cells
  • Table 3.5: Breakout of the Stem Cell Research Market: Research Efforts with Different Types of Stem Cells in 12 to 18 Months
  • Table 3.6 Publicly-Held Stem Cell Companies
  • Table 3.7: Market Shares of Companies/Institutions Offering Different Stem Cells to Researchers
  • Table 3.8: Market Shares of Companies/Institutions Offering Reagents for Stem Cell Research
  • Table 3.9: Privately-Held Stem Cell Companies
  • Table 3.10: Product and Custom Service Providers in the Stem Cells Space
  • Table 3.11: Cord Blood Stem Cell Companies
  • Table 3.12: Adult Stem Cell Companies
  • Table 3.13: Reagents, Media and Consumable Companies
  • Table 3.14: Stem Cells Research Market Forecast, 2006-2011
  • Table 4.1: Worldwide Market for Flow Cytometry Instruments and Reagents, 2000-2010
  • Table 4.2: Leading Players in Flow Cytometry Instrumentation
  • Table 5.1: Leading Stem Cell Companies
  • Table 6.1: Hematopoietic Cytokines
  • Table 6.2: Skin Rejuvination (Aesthetics) Markets, 2005-2012
  • Table 6.3: Burn Scars Markets, 2005-2012
  • Table 6.4: Acne Scars, 2005-2012
  • Table 6.5: NYHA Classifications for Stages of Heart Failure
  • Table 6.6: Worldwide Market for Cardiac Care Therapeutics, 1999-2010
  • Table 6.7: Examples of Cell Types Used in Cardiac Repair
  • Table 6.8: Clinical Trials of MyoCell
  • Table 6.9: The Common Metrics Used to Evaluate the Efficacy of These Therapies Include
  • Table 6.10: Stemline™ Platform Media for Expansion and Maturation of Stem Cells
  • Table 6.11: Gene Transfer Vehicles
  • Table 7.1: Investment in Stem Cell Research in Different Countries
  • Table 7.2: International Location of hESC Lines
  • Table 7.3: Unpublished Lines (Not Peer-Reviewed)
  • Table 8.1: Delivery of Cells for Heart Repair Technologies

LIST OF FIGURES

  • Figure 2.1: Release of Leukocytes into the Bloodstream
  • Figure 2.2: Derivation of Embryonic Stem Cells (ESCs) from the Inner Cell Mass of Blastocysts
  • Figure 2.3: Classification of Stem Cells: Embryonic Stem Cells versus Adult Stem Cells
  • Figure 2.4: Somatic Cell Nuclear Transfer (SCNT)
  • Figure 2.5: Segmentation of the Stem Cells Marketplace Based upon Commercial Offerings-Products and Services
  • Figure 2.6: Geographical Breakout of Stem Cell End-user Survey Respondents
  • Figure 2.7: Affiliation (Pharma, Biotech, Academic/University) of Stem Cell End-user Survey Respondents
  • Figure 2.8: Most of the Survey Respondents are Studying Stem Cells or Using Stem Cells in Their Research
  • Figure 2.9: Length of Time Survey Respondent Pool Studying Stem Cells or Using Stem Cells in Their Research Activities
  • Figure 2.10: Utilization/Research with Different Stem Cell Types
  • Figure 2.11: Range of Number of Experiments Involving Stem Cells Conducted per Week
  • Figure 2.12: Do the two Sub-Populations of Researchers Occupying the Two Ends of the Throughput Scale Exhibit Differences with Respect to Usage of Different Stem Cell Types?
  • Figure 2.13: How Much Research Dollars Are Spent Monthly on Research/Studies with Different Stem Cell Types
  • Figure 2.14: Growth of Research Spending in Various Segments of the Stem Cells Space (Defined by Stem Cell Type)
  • Figure 3.1: Global Forecast of Revenues for Stem Cell and Cytokine Therapies in Regenerative Medicine, 2003-2010
  • Figure 3.2: Stem Cell Research Market, 2006-2011
  • Figure 3.3: Growth in End-User Utilization of the Various Different Stem Cell Types
  • Figure 3.4: Breakout of the Stem Cell Research Market: Current Research Efforts with Different Types of Stem Cells
  • Figure 3.5: Breakout of the Stem Cell Research Market: Research Efforts with Different Types of Stem Cells in 12 to 18 Months
  • Figure 3.6: Broad Classification of Research Activities Being Performed with Stem Cells by Researchers
  • Figure 3.7: Current End-User Utilization Category of Adult Stem Cells (ASCs)
  • Figure 3.8: Current End-User Utilization Category of Human Embryonic Stem Cells (hESCs)
  • Figure 3.9: Current End-User Utilization Category of Human Cord Blood Stem Cells
  • Figure 3.10: Current End-User Utilization Category of Animal Stem Cells
  • Figure 3.11: Current End-User Utilization Category of Cancer Stem Cells
  • Figure 3.12: Challenges in the Study or Utilization of Adult Stem Cells (ASCs)
  • Figure 3.13: Challenges in the Study or Utilization of Human Embryonic Stem Cells (hESCs)
  • Figure 3.14: Challenges in the Study or Utilization of Human Cord Blood Stem Cells
  • Figure 3.15: Challenges in the Study or Utilization of Animal Stem Cells
  • Figure 3.16: Challenges in the Study or Utilization of Cancer Stem Cells
  • Figure 3.17: Top Unmet Needs in Commercial Products in the Stem Cells Research Space
  • Figure 3.18: Stem Cells Research Market, 2006-2011
  • Figure 4.1: Cell Microencapsulation: Promise and Progress
  • Figure 6.2: Ceregene Pipeline of Products
  • Figure 7.1: FDA Review Centers
  • Figure 7.2: World Map of Stem Cell Regulations
Back to Top